Risedronate for prevention and treatment of osteoporosis in postmenopausal women

Robert R. Recker, Janet Barger-Lux

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Risedronate sodium is an N-containing bisphosphonate that has been approved for the prevention and treatment of osteoporosis in postmenopausal women. An increase in the rate of bone remodelling is a regular feature of oestrogen withdrawal during the menopausal transition, but excessive remodelling leads to bone fragility. Risedronate and similar compounds reduce the rate of bone remodelling by suppressing the action of osteoclasts. The antifracture efficacy of risedronate is impressive. In large clinical trials of postmenopausal women with osteoporosis-related fracture(s) at entry, the risk of incident vertebral and non-vertebral fractures was reduced by ∼ 40%. In older women at risk for hip fracture, incident hip fractures were also reduced by ∼ 40%. Antifracture efficacy develops within the first 6 months, and treatment has been followed for as long as 5 years without deleterious effects on bone. We await reports of experience with risedronate in 'real-world' cases of greater complexity (i.e., in patients with co-morbidities and medications that would have excluded them from published clinical trials.

Original languageEnglish (US)
Pages (from-to)465-477
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Issue number3
StatePublished - Mar 1 2005

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Risedronate for prevention and treatment of osteoporosis in postmenopausal women'. Together they form a unique fingerprint.

Cite this